Concepedia

Publication | Open Access

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

DOIFull Paper Access

85

Citations

27

References

2010

Year

Antonio Gualberto, Mary L. Hixon, Daniel D. Karp, D Li, S Green, Marisa Dolled‐Filhart, Luis Paz‐Ares, Silvia Novello, Johnetta Blakely, Corey J. Langer,
British Journal of Cancer

Abstract

Free IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy.

References

YearCitations

Page 1